Treatment with Imaavy (nipocalimab-aahu) has led to sustained disease control for up to 1.5 years among adolescents with generalized myasthenia gravis (gMG), according to data from the long-term extension (LTE) part of a Phase 2/3 clinical trial. The study, called Vibrance-MG (NCT05265273), is now evaluating Imaavy’s safety…
Weekly treatment with gefurulimab —an investigational C5 inhibitor from Alexion, Astrazeneca Rare Disease, that’s designed to be self-administered — led to early and sustained reductions in disease severity for adults with generalized myasthenia gravis (gMG), according to top-line data from a Phase 3 clinical trial. The findings…
Vyvgart (efgartigimod alfa-fcab) led to significant and clinically meaningful reductions in disease severity among adults with generalized myasthenia gravis (gMG) who test negative for disease-causing antibodies targeting the acetylcholine receptor (AChR). Notably, benefits were seen across different subgroups of anti-AChR antibody-negative patients, who are also known as having…
Vyvgart (efgartigimod alfa-fcab), currently approved in the U.S. for treating certain adults with generalized myasthenia gravis (gMG), safely eased disease severity in adolescents with the disease, according to new data from a Phase 2/3 trial. Called ADAPT JR (NCT04833894), the study is still recruiting younger children,…
Neurologists consider the degree of clinical efficacy and the onset of action as the most important factors when making treatment decisions for their patients with generalized myasthenia gravis (gMG), according to a study. Still, there is variability, with some physicians considering the mode of treatment administration a more important…
Daily treatment with Zilbrysq (zilucoplan) was safe and effective in people with generalized myasthenia gravis (gMG) who were switching from Soliris (eculizumab) or Ultomiris (ravulizumab-cwvz), according to results from a small U.S. clinical trial. All of these medications belong to a class of therapies…
The recently approved prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that offers the possibility of self-administration is now available in the U.S. for eligible adults with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChRs). These ready-to-use syringes are intended to be…
The U.S. Food and Drug Administration (FDA) has approved nipocalimab as a treatment for adults and adolescents, ages 12 and older, with generalized myasthenia gravis (gMG) who have antibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) proteins. The newly approved therapy will be sold by developer…
Disease-causing antibodies from different myasthenia gravis (MG) patients bind to and affect the function of acetylcholine receptors (AChRs) in different ways, a study finds. While the mechanism varied, all the antibodies ultimately interfered with the usual activation of AChRs, which are the proteins important for normal muscle contractions commonly…
The U.S. Food and Drug Administration (FDA) has approved a version of Argenx’s Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that can be self-administered via a prefilled syringe to treat generalized myasthenia gravis (gMG). These prefilled syringes are indicated for adults with gMG who are positive for antibodies against…
Get regular updates to your inbox.
